ArticleBMJ case reports2020
Clinical course of COVID-19 among immunocompromised children: a clinical case series.
Article in BMJ case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The impact of immunocompromise on outcomes of COVID-19 in children and young people-a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Prolonged viral shedding in feces of children with COVID-19: a systematic review and synthesis of data.European journal of pediatrics · 2022Pooled it
- Risk Factors for Severe COVID-19 in Children: A Systematic Review and Meta-Analysis.Journal of Korean medical science · 2022Pooled it
- COVID-19 clinical outcomes in pediatrics: Comparison between immunocompromised and immunocompetent patients in ColombiaBiomedica : revista del Instituto Nacional de Salud · 2026Article
- Rapid Recovery From SARS-CoV-2 Infection Among Immunocompromised Children Despite Limited Neutralizing Antibody Response: A Virologic and Sero-Immunologic Analysis of a Single-Center Cohort.Journal of Korean medical science · 2025Article
- Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: A systematic review and individual patient meta-analysis.EClinicalMedicine · 2022Article
- Mild and Asymptomatic Coronavirus Disease in Children, Adolescents, and Household Contacts and Prolonged Viral Excretion.International journal of microbiology · 2022Article
- SARS-CoV-2 persistence in immunocompromised children.Pediatric blood & cancer · 2021Article
- Impact of COVID-19 on Pediatric Immunocompromised Patients.Pediatric clinics of North America · 2021Review
- Clinical Profile and Outcome of COVID-19 Among Immunocompromised Children.Indian pediatrics · 2021Article
- Progress in the Diagnosis and Treatment of COVID-19 in Children: A Review.International journal of general medicine · 2021Review
- Allogeneic Hematopoietic Stem Cell Transplant for Acute Lymphoblastic Leukemia in a Pediatric Patient After COVID-19 Infection Complicated by MIS-C.Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & PractitionersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with SARS-CoV-2 represents a great source of concern and a new threat for immunocompromised patients. Limited studies are available on COVID-19 in immunocompromised children. This case series aimed to evaluate the clinical and laboratory characteristics, management and outcomes of COVID-19 in five children immunocompromised due to different underlying conditions. All had mild symptoms or were asymptomatic at presentation. All had a benign course of illness. No changes or delays in their treatment regimens occurred, and none experienced a relapse of the original disease, developed severe COVID-19 or died. However, these cases showed a prolonged duration of virus shedding. This report suggests that immunocompromised paediatric patients may not be at a higher risk of developing severe COVID-19. However, further studies are required to elaborate on the pathogenesis of COVID-19 in this vulnerable group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.